Watch our recent interview with Yeon Hee Park at #ASCO26 to hear about exploratory analysis from DESTINY-Breast09 of first-line trastuzumab deruxtecan + pertuzumab in HER2+ advanced or metastatic #BreastCancer 🧬 🩺

🔗

#Oncology #BCSM #TrialUpdate

DESTINY-Breast09: treatment duration & outcomes by best response in HER2+ mBC

Yeon Hee Park, MD, Samsung Medical Center, Seoul, South Korea, discusses an exploratory analysis from DESTINY-Breast09 ...

ow.ly

What do the results of the NorthStar study suggest about the future of local consolidation therapy in the treatment of EGFR-mutated #LungCancer?⭐

Find out from Saumil Ghandi, who explored the results with us at #ELCC26🫁

Watch:

#Oncology #TrialUpdate

Local consolidation and systemic therapy combinations in EGFR-mutated lung cancer

Saumil Ghandi, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, explores the future of local c...

ow.ly

How do surgical resection and #SBRT compare in patients with stage IV #NSCLC?🤔

@kushal_kriplani presents findings from a retrospective real-world outcomes study comparing the techniques at #ASCO26 🌎🫁

Watch:

#Oncology #LungCancer #LCSM #SurgOnc

Surgical resection versus SBRT in stage IV NSCLC: survival outcomes from real-world data

Kushal Kriplani, MBBS, SUNY Downstate Health Sciences University, Brooklyn, NY, discusses the results of a retrospective...

ow.ly

Chinmay Jani (@Jani_Chinmay) at #ASCO26 describes the design of a dose-escalation and cohort-expansion Phase I trial evaluating intratumoral oncolytic virus SVV-001 with ipi + nivo in high-grade #NeuroendocrineNeoplasms 💉🦠

Watch:

#Oncology #ImmunoOnc

Oncolytic virus SVV-001 plus nivolumab and ipilimumab in high-grade NENs

Chinmay Jani, MBBS, Sylvester Comprehensive Cancer Center, Doral, FL, describes the design of a Phase I dose-escalatio...

ow.ly

In an interview at #ASCO26, Zhonglin Hao shares preliminary findings from an ongoing dose-escalation study of LB2102, a DLL3-targeted autologous #CAR-T cell therapy in patients with #SCLC or #LCNEC 💉🫁

Watch:

#Oncology #CART #LungCancer #LCSM @ASCO

Phase I trial of LB2102 CAR-T therapy in R/R SCLC and LCNEC

Zhonglin Hao, MD, PhD, University of Kentucky, Lexington, KY, presents preliminary findings from an ongoing Phase I ...

ow.ly